The PHILA trial demonstrated a benefit in terms of PFS derived from the addition of pyrotinib to first-line trastuzumab + chemotherapy in patients with metastatic HER2-positive breast cancer; however, the increasing risk of gastrointestinal toxicity should be carefully assessed [72]. Here, ERBB2 is linked to breast carcinoma.